| __timestamp | Apellis Pharmaceuticals, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 24518692 |
| Thursday, January 1, 2015 | 6356782 | 19886580 |
| Friday, January 1, 2016 | 4303743 | 12631689 |
| Sunday, January 1, 2017 | 10463151 | 21977998 |
| Monday, January 1, 2018 | 22639184 | 20759000 |
| Tuesday, January 1, 2019 | 67046483 | 20838000 |
| Wednesday, January 1, 2020 | 139401000 | 121812000 |
| Friday, January 1, 2021 | 176771000 | 152137000 |
| Saturday, January 1, 2022 | 277163000 | 83231000 |
| Sunday, January 1, 2023 | 500815000 | 122706000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, TG Therapeutics, Inc. and Apellis Pharmaceuticals, Inc. have taken different paths in optimizing these costs.
From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A expenses, growing by over 17,000% from 2014 to 2023. In contrast, TG Therapeutics maintained a more stable trajectory, with expenses peaking in 2021 before declining by 45% in 2022.
While Apellis's rising costs may reflect aggressive expansion and investment in growth, TG Therapeutics' more controlled spending suggests a focus on efficiency. Investors and stakeholders should consider these trends when evaluating the companies' long-term strategies and financial health.
Breaking Down SG&A Expenses: Johnson & Johnson vs TG Therapeutics, Inc.
AbbVie Inc. or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
argenx SE or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs TG Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights